PD 138312

Drug Profile

PD 138312

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Antibacterials; Fluoroquinolones; Naphthyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 21 Jan 2008 Discontinued - Phase-I for Bacterial infections in USA (unspecified route)
  • 15 Jan 2004 No development reported - Phase-I for Bacterial infections in USA (unspecified route)
  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top